Skip to content
AusGrant
Federal Forecasted GRANTS-GOV-364219

Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed)

National Institutes of Health (NIH) · Competitive · Science & Technology

At a glance

Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed) is a federal competitive grant from National Institutes of Health for the science & technology sector. Funding: $12M total. Eligible applicants: Public and State controlled institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; City or township governments; Private institutions of higher e. Applications are accepted on a rolling basis. Apply via the official listing at www.grants.gov.

Amount
$12M total
Deadline
Rolling
Type
Competitive
Status
Forecasted

About this program

This NOFO will support research using human-relevant New Approach Methodologies (NAMs) to advance understanding of the earliest events that initiate and drive Type 1 Diabetes (T1D). Projects will use human cells and tissues and innovative experimental and computational approaches–including organoids, microphysiological systems, and other advanced human-relevant models–to investigate cellular and molecular mechanisms involved in T1D initiation and early disease progression. The research is expected to identify and validate early biomarkers and therapeutic targets and advance new strategies to prevent or interrupt disease progression before substantial pancreatic beta cell loss occurs.Funded projects will become part of the Human Islet Research Network (HIRN), providing a collaborative environment that brings together complementary expertise, technologies, human biological resources, and datasets. Awardees will be expected to participate in collaborative activities, share tools and data, coordinate the use of scarce human pancreatic tissues, and promote harmonization and interoperability of approaches and datasets where appropriate. Through this coordinated research effort, the initiative seeks to overcome barriers that have limited progress by individual laboratories and accelerate the translation of discoveries about early human T1D into biomarkers, therapeutic targets, and ultimately preventive or treatment strategies.

Who can apply

Public and State controlled institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; City or township governments; Private institutions of higher education; Others (see text field entitled "Additional Information on Eligibility" for clarification); Native American tribal organizations (other than Federally recognized tribal governments); For profit organizations other than small businesses; State governments; Native American tribal governments (Federally recognized); Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; Special district governments; County governments; Independent school districts; Public housing authorities/Indian housing authorities. Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

How to apply

Apply through Grants.gov using funding opportunity number RFA-DK-28-113. Register your organization (SAM.gov + Grants.gov) before the deadline, then submit the application package listed in the official notice.

Apply at official source